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Objectives:  The  purpose  of  this  study  was  to examine  the  relationship  between  apolipoprotein  (a)  isoforms
and  early  atherosclerosis,  assessed  by  carotid  artery  intima-media  thickness  in  a  sample  of adults  of  the
general  population  of  Burgos,  a city  in  the  north  of  Spain.
Design  and  methods:  Lipids,  lipoprotein  (a), number  of  carotid  atherosclerotic  plaques,  if any,  and  the
intima-media  thickness  in the  far wall  of both  common  carotid  arteries  by  B-mode  ultrasound  were
determined  in  a group  of  171  adults  from  the  general  population  of Burgos,  Spain.  Apolipoprotein  (a)
isoforms  were  determined  in  a random  subset  of  119  subjects.
Results:  Increasing  age,  male  sex, and  past  personal  cardiovascular  history  were  signiﬁcantly  associatedntima media thickness
arly atherosclerosis
arotid artery
with  increased  left,  right,  or average  intima-media  thickness  of both  carotid  arteries  in  multivariate
analysis.
No  statistically  signiﬁcant  association  was  found  between  apolipoprotein  (a)  isoforms  and mean  carotid
intima-media  thickness  by bivariate  or multivariate  regression  analysis.
Conclusions:  In this  sample  of  the  general  Spanish  population,  no association  was  found  between
apolipoprotein  (a)  isoforms  and  carotid  artery  intima-media  thickness.
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ntroduction
Intima-media thickness (IMT) is an echographic measurement
hat estimates both inner arterial layers (intima and media) where
theroma begins, and therefore it is considered a good measure of
theroma in its initial stages. Both carotid atherosclerotic plaques
nd increased common carotid artery IMT  are associated with a
igher risk of ischemic stroke, presence and severity of coronary
rtery disease, and cardiovascular mortality [1–4]. A review of
ight epidemiological studies showed that the IMT  of the common
arotid artery had independent predictive power with respect to
ardiovascular events [5].
Lipoprotein (a) [Lp (a)], an emerging risk factor for cardio-
ascular disease, is a cholesterol rich lipoprotein composed of a
ow-density lipoprotein (LDL) particle and a highly polymorphic
polipoprotein (a) [Apo (a)], which is covalently linked to the
polipoprotein-B moiety of the LDL by a single disulphide bridge.
Apo (a) shares a striking structural similarity to plasminogen [6]
nd contains multiple repeated copies of a sequence that closely
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resembles plasminogen kringle 4 (KIV), followed by two  sequences
homologous to kringle V and serine protease domains of plasmino-
gen, respectively.
The KIV-like sequences can be classiﬁed into 10 types, based
on amino acid sequence. Each Apo (a) molecule contains a single
copy of KIV types 1 and 3–10, but variable identical repeats (3 to
more than 40) of kringle IV type 2, thus leading to different Apo (a)
isoforms sizes [7,8], with molecular weights ranging from 280 to
800 kDa.
The concentration of Lp (a) is controlled by a single gene in the
region 6q26-27 with multiple alleles, and each allele inﬂuences the
concentration of Lp (a) differently [9], according to the number of
expressed kringle IV repeats [10,11]. Other sequence variations of
the Apo (a) locus may  also inﬂuence Lp (a) plasma levels.
Lp (a) phenotypes have different functional properties as
regards lysine binding afﬁnity, the small Apo (a) isoforms show-
ing the greatest afﬁnity for ﬁbrin [12], suggesting that the low
molecular weight (LMW)  Apo (a) isoform’s size itself plays a role in
atherogenesis [12].
Although a relationship has frequently been reported between
Apo (a) isoforms with less than 22 KIV repeats and cardio- or
cerebro-vascular diseases [13–15], few studies have investigated
the relationship between phenotypes of Apo (a) and carotid artery
IMT. In this study the association between Apo (a) isoforms and
vier Ltd. All rights reserved.
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arotid IMT  in a group of individuals from the general population
f Burgos, northern Spain was studied.
aterials and methods
opulation studied
This study was performed on 171 subjects randomly selected
rom the records of the 200,000 referral population of “Gamonal
ntigua” Health Care Center of the city of Burgos, and their age and
ex percentage distribution were those of the Spanish population in
he 2004–2010 census. A sample size of 180 individuals was calcu-
ated in order to have an alpha error of 0.05, a power of 60% to detect
 0.2 mm difference from a normal IMT  of 0.65 mm ± 0.15 mm and
 10% of expected losses of recruited participants. After data collec-
ion, losses were less than predicted, 9 participants, thus leaving
71 subjects valid for analysis.
Apo (a) isoforms were determined in a subset of 119 randomly
elected subjects due to economic limitations. Lp (a) levels and
stablished cardiovascular risk factors, such as blood pressure,
otal cholesterol, high-density lipoprotein (HDL)-cholesterol, LDL-
holesterol, and triglycerides were also determined.
Blood pressure was assessed by the mean of two systolic and
iastolic readings after 10 min  of rest in the supine position.
ypertension was deﬁned as a systolic/diastolic blood pres-
ure > 140/95 mm Hg or current use of antihypertensive drugs.
Body mass index (BMI), waist-to-hip ratio, and demographic
ata were also recorded. A standardized questionnaire on cur-
ent and past personal or familial cardiovascular history, alcohol or
obacco consumption, sociodemographic variables, diabetes melli-
us, or other previous disease was completed by each participant.
Informed consent for the procedures to be used was obtained
rom each subject. The study was approved by the Clinical Studies
ommittee of the referral hospital.
nalytical methods
Venous blood samples were obtained under standardized con-
itions and after 12 or more hours of fasting. Total cholesterol
nd triglycerides where determined enzymatically (Roche Diag-
ostics, Basel, Switzerland), LDL-cholesterol using the Friedewald
ormula, and very low-density lipoprotein (VLDL)-cholesterol by
ividing the triglyceride concentration by 2.18. Both LDL- and
LDL-cholesterol were calculated in mmol/l.
Lp (a) in serum was quantiﬁed by a commercially avail-
ble rate nephelometry method (Siemens, Marburg, Germany)
ith an analytical sensitivity of 0.002 g/l, no cross-reactivity with
polipoprotein B (<1%), a <5% cross-reactivity with plasminogen,
nd minimally affected by Apo (a) isoforms size heterogeneity [16].
Apo (a) phenotypes were determined by sodium dodecyl
ulphate (SDS) polyacrylamide gel electrophoresis (PAGE) and
mmunoblotting by a method modiﬁed from that described by
termann et al. [17] according to Kraft et al. [18].
The samples were prepared by mixing 10 l of serum with 85 l
f a buffered solution and 5 l of -mercaptoethanol. Aliquots of
amples were then subjected to SDS PAGE in a 4–15% gradient
olyacrylamide gel. The separated proteins were transferred to
 nitrocellulose membrane and antigens were visualized on the
itrocellulose membrane by a double-antibody procedure. The ﬁrst
ntibody was a polyclonal antihuman Lp (a), which is raised in
heep. The second antibody was an anti-sheep immunoglobulin G
ntibody conjugated to alkaline phosphatase. When the appropri-
te substrate was applied the bands became visible.
The different isoforms of Lp (a) were designated according to
heir electrophoretic mobility on SDS PAGE relative to a mix  of ﬁveiology 61 (2013) 372–377 373
recombinant Apo (a) isoforms containing kringles 35, 27, 23, 19,
and 14 KIV repeats that was  used as standard reference.
The Apo (a) phenotypes were stratiﬁed into 2 subgroups accord-
ing to the molecular weight of the smaller Apo (a) isoform, the LMW
Apo (a) phenotype was  determined by the occurrence of at least 1
Apo (a) isoform with 11–22 KIV repeats, and the high molecular
weight (HMW)  Apo (a) phenotype when all isoforms had >22 KIV
repeats as they are conventionally designated [19].
Intima-media thickness determination
IMT  was determined by B-mode ultrasound in the far wall of
the left and right common carotid arteries, 1 cm proximal to its
bifurcation. The ultrasound equipment was an HP Image Point
(Hewlett-Packard, Palo Alto, CA, USA) with a 10 MHz linear probe
that was placed on the neck of the subjects who lay supine, par-
allel to its longitudinal axis, in an anterolateral plane (60◦ angle,
with 0◦ being the horizontal). Each IMT  measurement was  per-
formed twice in both the left and right carotid of each subject,
and the average right and left carotid IMT  calculated. Measure-
ments were conducted blind to the rest of the data, by the same
investigator. An atheroma plaque was deﬁned echographically as a
hyperechogenicity or protrusion in the vascular lumen of the intima
of at least twice the thickness of the adjacent intima media.
Statistical analysis
For each variable, the validity of assumption of normality was
checked. This assumption held true for all variables, except for
IMT, waist-to-hip ratio and Lp (a) concentration, in which results
are expressed as medians and interquartile ranges (IR). In the rest,
results are expressed as means ± standard deviation (SD).
To assess the relationship between IMT  and Lp (a), a bivariate
linear regression analysis was performed. The same analysis of IMT
and secondary independent variables such as age, BMI, waist-to-
hip ratio, systolic blood pressure, HDL-cholesterol, LDL-cholesterol,
plasma triglycerides, and fasting glucose followed. To determine
the association of Lp (a) and IMT  after adjusting for secondary inde-
pendent variables, a multivariate linear analysis was  performed in
which nominal variables such as gender and current or past per-
sonal or familial cardiovascular history were included as dummy
variables.
IMT, age, Lp (a), and conventional analytical or anthropomet-
ric cardiovascular risk factors were compared between >22 k4 and
≤22 k4 repeats groups, using the Student’s t-test when normally
distributed or if not by the Mann–Whitney test as in the case of
IMT, Lp (a), and waist-to-hip ratio.
We examined the association between IMT  and Lp (a) carrying
differently sized Apo (a) isoforms using multivariate linear regres-
sion analysis.
The Spearman’s rank correlation coefﬁcient was  used to mea-
sure the statistical dependence between the molecular weight of
the different isoforms of Apo (a) and the mean of the right and left
IMT.
To determine the combined effect of increased Lp (a) concentra-
tions and LMW,  Apo (a) phenotypes were stratiﬁed into 4 groups
according to Lp (a) concentrations (cut-off point 300 mg/l) and Apo
(a) phenotypes (cut-off point 22 KIV repeats). All p-values less than
0.05 were considered to indicate statistical signiﬁcance.
Statistics were calculated using the program SPSS 15 (SPSS Inc.,
Chicago, IL, USA).Results
Anthropometric and lipoprotein parameters are shown in
Table 1. Lp (a) ranged from 10 to 1060 mg/l (IR = 307.5) with a
374 P. Calmarza et al. / Journal of Card
Table 1
Anthropometric and lipoprotein parameters.
Variables N Descriptive statisticsa
Age (years) 171 63 (20)
Weight (kg) 171 72.11 ± 11.80
BMI  (kg/m2) 170 28.13 ± 3.69
Waist to hip ratio 130b 1.4 ± 0.2
CVD personal history 170b 18 (10,53%)
SBP (mmHg) 170b 140.67 ± 17.6
DBP (mmHg) 169b 80.43 ± 10.48
Total cholesterol (mmol/l) 171 5.53 ± 1.06
HDL  cholesterol (mmol/l) 171 1.51 ± 0.4
LDL  cholesterol (mmol/l) 171 3.43 ± 0.89
Triglycerides (mmol/l) 168b 1.08 (0.62)
Lp(a) (mg/l) 168b 150 (307.5)
Fasting glucose (mmol/l) 171 5.16 (0.89)
Right mean IMT  (mm)  169b 0.73 (0.23)
Left mean IMT (mm) 169b 0.76 (0.22)
Overall mean IMT  (mm)  169b 0.74 (0.22)
Subjects with at least one plaque 171 41 (24%)
a Nominal variables are expressed as percentages and quantitative variables are
expressed as means ± standard deviation except for waist to hip ratio, triglycerides,
Lp(a), glucose and IMT  expressed as median (interquartile range). Abbreviations:
N,  number of subjects; BMI, body mass index; SBP, systolic blood pressure; DBP,
diastolic blood pressure; CVD, cardiovascular disease; HDL, high density lipoprotein;
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iDL, low density lipoprotein; Lp(a), Lipoprotein (a); IMT, intima-media thickness.
b The total number of patients does not sum up to 171 due to 31, 1, 2 or 3 missing
alues.
istribution skewed to lower values both in men  and women. Age
anged from 44 to 93 years (mean 64.2 ± 12 years) and mean IMT  of
oth carotid arteries from 0.53 mm to 1.27 mm (median 0.74 mm,
R = 0.22); 41 individuals (24%) had one or more atherosclerotic
laques.
Bivariate analysis showed that older age, male gender, higher
MI, higher waist-to-hip ratio, and elevated systolic blood pres-
ure were associated with higher values of IMT, but in multivariate
inear regression analysis, only older age, male sex, and past cardio-
ascular history were signiﬁcantly associated with increased left,
ight, or average IMT  of both carotid arteries (Table 2).
No relationship was found between IMT  and Lp (a) levels in the
nivariate or multivariate analysis.
When we categorized Lp (a) levels into quartiles, we  did not
nd thicker IMT  in the higher quartiles of Lp (a) values and when
e dichotomized Lp (a) into higher or lower than 300 mg/l groups,
here were no differences in the number of plaques (or their thick-
ess when present). Lp (a) in individuals with LDL-cholesterol
evels in the highest quartile was not associated with a thicker IMT
ompared with people with LDL-cholesterol in the lowest quartile.
Lp (a) concentrations were inversely associated with the molec-
lar weight of Apo (a) isoforms: Lp (a) concentrations were highest
n individuals with Apo (a) phenotypes of LMW,  in which Lp
a) concentrations were signiﬁcantly higher compared with high
olecular weight Apo (a) isoform individuals (p < 0.001).
able 2
isk factors affecting carotid atherosclerosis. Multivariate linear regression analysis.
Variables in the best explanation model Right mean IMT
N = 168
R2 = 0.414
B 95%CI 
Age (years) 0.009* 0.007/0.011 
Sex  (male vs. female) 0.080* 0.040/0.120 
BMI  (kg/m2) 
SBP  (mmHg) 
CVD  personal history 0.061 −0.005/0.128 
LDL-Chol (mmol/l) 0.020 −0.003/0.043
bbreviations:  IMT, intima-media thickness; N, number; R2, coefﬁcient of determination; 
nterval; BMI, body mass index; SBP, systolic blood pressure; CVD, cardiovascular disease
* p-Value < 0.05.iology 61 (2013) 372–377
In 100 subjects (85.5%), only one Apo (a) isoform was detected,
whereas two isoforms were found in 17 subjects (14.5%). Serum Lp
(a) concentrations were signiﬁcantly higher (p < 0.001) in “double
band” subjects (487.65 mg/l) as compared to those with a single Apo
(a) isoform (211.90 mg/l). There was a non-signiﬁcant tendency of
having one or more plaques in homozygous subjects (25.5%) com-
pared to heterozygous subjects (5.9%) (p = 0.061).
Table 3 shows anthropometric and lipoprotein parameters
when Apo (a) size was dichotomized into less than or greater than
22k. Apart from the difference in Lp (a) concentrations already men-
tioned, there were no differences between the groups in any other
parameter studied.
IMT  did not differ between subjects with LMW  Apo (a) isoforms
(IMT 0.71 mm)  and HMW  isoforms (IMT 0.72 mm), and between
subjects with different Lp (a) levels or phenotypes. Number of
plaques also did not differ among these groups.
In the subgroup with LDL-cholesterol levels in the highest quar-
tile (LDL-C ≥ 39.57 mmol/l), LMW  Apo (a) isoforms and IMT were
also not associated.
Fig. 1 shows the average IMT  according to the approximate
molecular weights of the different isoforms of Apo (a).
The range of Lp (a) values was wider (20–1040 mg/l) within
LMW  (≤22k) Apo (a) isoforms than within the HMW  (>22k) group
in which Lp (a) ranged from 10 to 320 mg/l (p < 0.001).
Also, when the study participants were stratiﬁed into 4 groups
according to low and high Lp (a) plasma concentrations (cut-off
point 300 mg/l) combined with HMW  and LMW  Apo (a) phenotypes
(cut-off 22 KIV repeats) there were no differences in the proportion
of subjects with one or more atherosclerotic plaques.
The group with LMW  Apo (a) phenotype and low Lp (a) plasma
levels showed a borderline, non-signiﬁcant trend to association
with the presence of one or more atherosclerotic plaques: relative
risk (RR) = 1.874; 95% CI 0.981–3.582.
Discussion
As a relationship between carotid IMT  and cardiovascular risk
factors is accepted [20], our ﬁnding of one association of older age,
male gender, BMI, waist-to-hip ratio, DBP, and personal cardiovas-
cular history (Table 2) is not unexpected.
On the contrary, the relationship between Lp (a) and early
atherosclerosis of carotid arteries is controversial. The exact mech-
anism by which Lp (a) increases cardiovascular risk is unknown
and both proatherogenic and prothrombogenic effects have been
hypothesized.The few studies addressing this issue have failed to demon-
strate a robust link between Lp (a) and surrogate markers of early
atherosclerosis, such as IMT  and brachial ﬂow-mediated arterial
dilation [20–25].
Left mean IMT
N  = 169
R2 = 0.451
Overall mean IMT
N  = 167
R2 = 0.461
B 95%CI B 95%CI
0.008* 0.007/0.010 0.008* 0.006–0.010
0.068* 0.02870.109 0.078* 0.043–0.114
0.004 −0.001/0.009
0.001* 0.000–0.002
0.072* 0.012/0.133 0.066* 0.007–0.125
B, regression coefﬁcient or carotid artery IMT  change (mm);  95%CI, 95% conﬁdence
; LDL, low density lipoprotein; Chol, cholesterol.
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Table  3
Lipids and lipoproteins levels in subjects with low and high molecular weight apolipoprotein (a) isoforms.
Total N Apolipoprotein (a) phenotypes
>22 kringles ≤22 kringles
Descriptive statisticsa Total N Descriptive statisticsa p
Age (years) 47 60.53 ± 11.53 72 62.24 ± 10.54 0.408
Sex  (male) 47 21 (44.68%) 72 31 (43.06%) 0.861
BMI  (kg/m2) 47 28.05 ± 3.73 72 28.32 ± 4.08 0.717
Waist  to hip ratio 35 1.4 (0.1) 59 1.32 (0.3) 0.680
CVD  Personal history 47 5 (10.64%) 72 8 (11.11%) 0.936
SBP  (mmHg) 46 139.26 ± 17.88 72 140.21 ± 19.05 0.785
DBP  (mmHg) 47 80.72 ± 10 72 80.97 ± 11.5 0.902
Total  cholesterol (mmol/l) 47 5.68 ± 1.09 72 5.47 ± 0.9 0.262
LDL  cholesterol (mmol/l) 47 3.57 ± 0.93 72 3.35 ± 0.83 0.168
HDL  cholesterol (mmol/l) 47 1.47 ± 0.3 72 1.53 ± 0.42 0.382
Triglycerides (mmol/l) 47 1.03 (0.44) 72 1.28 (0.81) 0.608
Lipoprotein (a) (mg/l) 47 100 (20) 70 315 (410) <0.001#
Fasting glucose (mmol/l) 47 5.27 (0.78) 72 5.16 (1.03) 0.442
Subjects with at least 1 atheromatous plaque 47 10 (21.28%) 72 17 (23.61%) 0.766
Overall mean IMT  (mm) 47 0.72 (0.15) 71 0.71(0.18) 0.947
Abbreviations: N, number of subjects; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; CVD, cardiovascular disease; HDL, high density
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fipoprotein; LDL, low density lipoprotein; Lp(a), Lipoprotein (a); IMT, intima-media
a Values are expressed as means ± standard deviation except for waist to hip rati
# p-Value < 0.05.
Considering the importance of genetic background in Lp (a)
evels, we attempted a population study in a Southern Europe
“Mediterranean”) country, randomly selecting the subjects, strat-
ﬁed in order to be representative of the Spanish population.
No relationship was found between Lp (a) levels and IMT
n bivariate or multivariate analysis, or when dichotomized into
igher or lower than 300 mg/l Lp (a) groups. Although Kotani and
akane [26] found an association between Lp (a) ≤300 mg/l in an
symptomatic group of individuals, they had a different genetic
ackground and sex distribution (Japanese women) than our study.
There was also an absence of relationship when analyzing the
therosclerosis risk in the high LDL-cholesterol subgroup, sug-
esting that Lp (a) does not potentate early atherosclerosis by
nteracting with LDL-cholesterol.
On the other hand, an analysis of 36 prospective studies,
ncluding more than 126,000 subjects, showed a linear association
ig. 1. Average intima media thickness of both carotid arteries according to the
pproximate molecular weights of the different apolipoprotein (a) [Apo (a)] iso-
orms.ness.
lycerides, Lp(a), glucose and IMT  expressed as median (interquartile range).
between Lp (a) levels and coronary and cerebrovascular disease,
independently from other conventional risk factors [27]. This
association with clinical events suggests that Lp (a) has a more
important role in fully developed, symptomatic atherosclerosis
[28,29] than in its early phase [20,22–25].
Because the association between Lp (a) and CHD (coronary
heart disease) is moderate in magnitude (RR of approximately
1.3 in a comparison between people in the top one-third and
those in the bottom one-third of the population distribution [27]),
certain subtypes of Lp (a) could be more strongly associated with
disease risk than others. It has been proposed that increased Lp (a)
concentrations and LMW  Apo (a) phenotypes may  synergistically
contribute to Lp (a) pathogenicity [30], but there are conﬂicting
reports on their relative roles in cardiovascular disease.
While the Physician’s Health Study demonstrated that small
Apo (a) size was an independent predictor of angina pectoris,
regardless of Lp (a) concentration, and without additive or syn-
ergistic effect [31], Dieplinger et al. [32] found a synergistic effect
between increased Lp (a) concentrations and the LMW Apo (a) phe-
notypes in subjects with symptomatic peripheral artery disease.
Our results cannot conﬁrm this: the group with high Lp (a) levels
and LMW  isoforms had no more atherosclerotic plaques than the
rest.
Similarly, Erqou et al. [33] in a systematic review of 40 studies
found that people with smaller molecular weight Apo (a) isoforms
had an approximately 2-fold higher risk of CHD and ischemic stroke
than those with higher molecular Apo (a) isoforms.
It remained unclear whether the deleterious vascular effect of
LMW  Apo (a) isoforms is primary or is due to higher Lp (a) concen-
trations that are associated with these isoforms [34,35].
There are few studies, as well as conﬂicting results on sub-
jects with subclinical arteriosclerosis: a sub-study of the ARIC
population found no differences in the Apo (a) phenotypes distri-
bution between individuals with preclinical extracranial carotid
atherosclerosis and those who  were free of carotid atherosclerosis
[36].
Similarly, the Bruneck study, a population-wide prospective
study of all 49–79 inhabitants of this Italian city in which Apo (a)
phenotypes also did not show a signiﬁcant association with early
carotid atherogenesis, but Apo (a) emerged as one of the strongest
risk predictors of advanced stenotic atherosclerosis [34]. Also, in
a recent study by Helgadottir et al. [37] no association was  found
between Apo (a) phenotypes and carotid IMT.
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In agreement with this, a signiﬁcant association between early
therosclerosis measured by IMT  and Apo (a) phenotypes was not
ound in this study.
Taken together, these studies, suggest that the effects of the Lp
a) variants, and thus Lp (a) levels are manifested at later stages in
he atherosclerotic process, and thereby are not reﬂected by varia-
ion in carotid IMT. In the same sense Abdullah et al. [38], studying
atients with coronary artery disease (CAD) compared to controls,
ound a number of gene candidates as potential biomarkers of CAD
n patients with different ethnicity and Atkov et al. [39] have devel-
ped an artiﬁcial neural network including traditional and genetic
actors of coronary heart disease.
The high variability of Lp (a) concentrations in subjects with
MW Apo (a) isoforms compared to subjects with HMW  Apo (a)
soforms found in our study, may  be due to the fact that the number
f k4 repeats is the main determinant of Lp (a) concentration when
his number is more than 22, whereas other polymorphisms may
e involved in the alleles with fewer than 22 k4.
The limitations of this study are a small sample size, that condi-
ions a relatively small statistical power, and that Apo (a) isoforms
ere determined in two thirds of the sample, but bias is not likely as
he subjects were randomly excluded. Although dedicated software
ay  be more exact in the measurement of IMT, repeated manual
easurements were made by the same investigator to decrease
ariability.
onclusions
The main conclusion of this study is a lack of association of Apo
a) isoforms with different IMT  of the carotid artery in a sample of
he general adult Spanish population.
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